drugset
drugset / Trial / NCT01650246

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246 ↗

Phase 3 Completed 143 enrolled Ardea Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.

Timeline

Start
2012-08
Primary completion
2014-04
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 400 mg —

Indications

gout